Severe hepatic side effects of ezetimibe

被引：44

作者：

Stolk, Mark F. J.

Becx, Marco C. J. M.

Kuypers, Karel C.

Seldenrijk, Cees A.

机构：

[1] St Antonius Hosp, Dept Gastroenterol, NL-3430 EM Nieuwegein, Netherlands

[2] St Antonius Hosp, Dept Pathol, NL-3430 EM Nieuwegein, Netherlands

[3] Mesos Med Ctr, Dept Gastroenterol, Utrecht, Netherlands

来源：

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2006年 / 4卷 / 07期

关键词：

PRIMARY HYPERCHOLESTEROLEMIA; CHOLESTEROL ABSORPTION; ATORVASTATIN; EFFICACY; SAFETY; RISK;

D O I：

10.1016/j.cgh.2006.04.014

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background & Aims: Ezetimibe was introduced recently as a new class of cholesterol-lowering drugs. Until now only limited increases of transaminase levels were reported. Methods: We studied 2 patients with severe hepatic side effects of ezetimibe in a general community hospital. Results: Ezetimibe may lead to 2 distinct types of severe hepatic side effects. Conclusions: Ezetimibe may rarely cause hepatotoxicity, severe cholestatic hepatitis, or acute autoimmune hepatitis.

引用

页码：908 / 911

页数：4

共 12 条

[1] Prevention and Rehabilitation - Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study
Ballantyne, CM
Abate, N
Yuan, Z
King, TR
Palmisano, J
[J]. AMERICAN HEART JOURNAL, 2005, 149 (03) : 464 - 473
[2] Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia
Ballantyne, CM
Blazing, MA
King, TR
Brady, WE
Palmisano, J
[J]. AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (12) : 1487 - 1494
[3] Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia - A prospective, randomized, double-blind trial
Ballantyne, CM
Houri, J
Notarbartolo, A
Melani, L
Lipka, LJ
Suresh, R
Sun, S
LeBeaut, AP
Sager, PT
Veltri, EP
[J]. CIRCULATION, 2003, 107 (19) : 2409 - 2415
[4] Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity
Chalasani, N
Aljadhey, H
Kesterson, J
Murray, MD
Hall, SD
[J]. GASTROENTEROLOGY, 2004, 126 (05) : 1287 - 1292
[5] Efficacy and safety of a potent new selective cholesterol absorption inhibitor, Ezetimibe, in patients with primary hypercholesterolemia
Dujovne, CA
Ettinger, MP
McNeer, JF
Lipka, LJ
LeBeaut, AP
Suresh, R
Yang, B
Veltri, EP
[J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (10) : 1092 - 1097
[6] Efficacy and safety of Ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia
Gagné, C
Bays, HÉ
Weiss, SR
Mata, P
Quinto, K
Melino, M
Cho, M
Musliner, TA
Gumbiner, B
[J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (10) : 1084 - 1091
[7] Ezetimibe - A review of its metabolism, pharmacokinetics and drug interactions
Kosoglou, T
Statkevich, P
Johnson-Levonas, AO
Paolini, JF
Bergman, AJ
Alton, KB
[J]. CLINICAL PHARMACOKINETICS, 2005, 44 (05) : 467 - 494
[8] Lammert F, 2005, GASTROENTEROLOGY, V129, P718, DOI [10.1053/j.gastro.2004.11.017, 10.1016/j.gastro.2004.11.017]
[9] Autoimmune hepatitis revealed by atorvastatin
Pelli, N
Setti, M
Ceppa, P
Toncini, C
Indiveri, F
[J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (08) : 921 - 924
[10] Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin
Stein, E
Stender, S
Mata, P
Sager, P
Ponsonnet, D
Melani, L
Lipka, L
Suresh, R
MacCubbin, D
Veltri, E
[J]. AMERICAN HEART JOURNAL, 2004, 148 (03) : 447 - 455

← 1 2 →